BELLEVUE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an important cell survival signaling pathway.
"PX-866 is a potent inhibitor of PI-3K, a component of a critical pathway that is activated in many types of cancer, leading to tumor growth and survival," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Oncothyreon. "We believe that the mechanism of action of PX-866, which irreversibly inhibits PI-3K, will have pharmacokinetic and pharmacodynamic advantages that will distinguish PX-866 in the competitive field of PI-3K inhibitors."
The Phase 1 trial is expected to enroll up to 63 patients with advanced metastatic cancer who have failed or are intolerant of standard therapy. Patients will receive PX-866 orally once per day on days 1 through 5 and 8 through 12 during a four-week treatment cycle. Primary objectives of the study include establishment of a maximum tolerated dose, evaluation of safety, and analysis of the pharmacodynamic and pharmacokinetic profiles of PX-866.
"The start of the PX-866 trial represents a significant milestone for
Oncothyreon, as we now have three active clinical programs underway for our
promising small molecule inhibitors," said Robert L. Kirkman, M.D.,
President and CEO of Oncothyreon. "Together with our therapeutic vaccine
programs, we have successfully established a broad and diverse oncology
pipeline targeting multiple cancer indications with substantial unmet
medical need, and we look forward to sharing the ongoing pro
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved